about
High intensity exercise decreases global brain glucose uptake in humansReproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data.Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.Expectation of caffeine induces dopaminergic responses in humans.Mobile phone affects cerebral blood flow in humans.Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease.Intravenous ethanol increases dopamine release in the ventral striatum in humans: PET study using bolus-plus-infusion administration of [(11)C]raclopride.Neuroanatomical substrata of amusement and sadness: a PET activation study using film stimuli.Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography.[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia.Visual assessment of [(11)C]PIB PET in patients with cognitive impairment.Research letter: Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder.The effects of lorazepam on extrastriatal dopamine D(2/3)-receptors-A double-blind randomized placebo-controlled PET study.Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography.Severe somatization in women is associated with altered cerebral glucose metabolism.Ketamine does not decrease striatal dopamine D2 receptor binding in man.Striatal dopamine D1 and D2 receptors in burning mouth syndrome.Striatal μ-opioid receptor availability predicts cold pressor pain threshold in healthy human subjects.Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects.Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study.Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans.Altered dopamine D2 receptor binding in atypical facial pain.Alfentanil increases cortical dopamine D2/D3 receptor binding in healthy subjects.Volumes of the caudate nuclei in women with somatization disorder and healthy women.Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride.Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease.Sevoflurane and propofol increase 11C-flumazenil binding to gamma-aminobutyric acidA receptors in humans.Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.The effects of xenon anesthesia on the relationship between cerebral glucose metabolism and blood flow in healthy subjects: a positron emission tomography study.The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects.Voxel-based analysis of cerebral glucose metabolism in mono- and dizygotic twins discordant for Alzheimer disease.PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment.Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457.Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia.Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study.PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.
P50
Q24547219-64CE9828-D560-4C04-9F43-E746BDA82C64Q33460473-E8C0C75E-9B05-4825-8912-68C0F5384639Q33987817-50459037-B53E-4C02-842C-61E24EFB8103Q34314230-89A1063C-B0FD-496E-AA42-F3605ABDDF47Q34497068-C306AE97-1CC4-4CDB-9602-C52190A8DE76Q34585068-B4354222-B5B3-4C6F-9DA6-2805347D69CDQ35143469-7BBC1197-667B-412C-B3ED-6F54C4D1A002Q38841866-0A006A40-4D3D-4FB7-8249-C7EFF8CD6B1FQ42652700-BD34C4B5-87B9-4882-A9EA-0115B7EAE68BQ42876603-F39B81BC-ECAF-41C1-82F0-F9A9797C276AQ43167831-2E520A81-FE5B-4268-A9BF-B055325DCC3DQ43244906-3B43DC8C-9197-40E2-9792-A9B4E4D9AF3CQ43257323-C4DD4537-55C9-4999-845C-B63748C46F33Q43281806-0526F001-17AA-4643-B342-88591B4FDDF3Q44096116-515DFF1E-1C78-4F23-B316-EC8C8A69F61AQ44232197-EAF5E287-C5B1-41C9-AE0B-1118DAFE0184Q44233094-CE0CA483-D582-472F-92B8-53F25861EF96Q44266718-E8F65096-F401-4B17-9EC1-9434B6081060Q44334363-A2FA4615-2FDD-43CF-AA85-EAE0F89FA94BQ44340060-0F4453BE-FBC4-4A85-A451-EA9D4AE4D1ABQ44455086-6F8274AF-79B1-4BC1-98AD-7154FAE2664FQ44576600-EC3BE5E7-392D-4A79-8F2D-1CAC4B20A93DQ44633724-DB76F663-C17C-4771-BAE9-6B33909E2F2CQ44843029-1B599078-61AC-47BA-8FD5-63E74C4D543FQ44972396-1A6987EF-DA50-448B-8757-3122DD56995FQ45021519-0E1A9422-3DFF-4483-B20A-38509C1A467CQ45076624-D8A81EA8-3530-4EF2-A9F6-8EB9B8F8DD41Q45122101-747BD27E-FE74-4D5B-A143-3832594DA75EQ45271401-6C8DAFC4-AD7C-40B1-9FC8-F44923862E81Q46101112-544C6960-02CA-463C-B6CB-3E994AB1D901Q46158581-4FC6F135-214B-49CD-B304-3E50A95BFC53Q46263889-A666913C-E728-4C00-8C9E-487D6BFB37B6Q46269271-FB7ABDF8-85E4-4115-82F6-4BF5E02B8889Q46309418-98CCA131-8E8E-4303-A33A-73FA272B2EB9Q46367916-254B000C-C9B4-487D-AF9A-ED6577AE4BD3Q46421438-172C8094-776C-4381-AFD2-CC1EE0CB70F2Q46430836-F6A8588A-1E3A-4440-8CC8-A8F184D6393CQ46516338-534A3E87-88FA-4AD9-943E-F60F87519F74Q46587017-BD7A8316-8E5C-46C1-A274-188A9353561CQ46628756-0C343697-C210-4EA8-9BD3-BE2B611EEDE8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sargo Aalto
@ast
Sargo Aalto
@en
Sargo Aalto
@es
Sargo Aalto
@nl
Sargo Aalto
@sl
type
label
Sargo Aalto
@ast
Sargo Aalto
@en
Sargo Aalto
@es
Sargo Aalto
@nl
Sargo Aalto
@sl
prefLabel
Sargo Aalto
@ast
Sargo Aalto
@en
Sargo Aalto
@es
Sargo Aalto
@nl
Sargo Aalto
@sl
P1053
K-1757-2013
P106
P31
P3829
P496
0000-0002-8924-5447